Metabolic syndrome (MS) is a significant modifiable risk factor for the development and progression of chronic kidney disease (CKD). The article presents data on the relationships between MS in general and its individual components with CKD. The key pathogenetic mechanisms of CKD development in MS are considered, including insulin resistance, obesity, hypertension, systemic inflammation and oxidative stress, neurohumoral activation, lipotoxicity. Diagnosis and treatment of CKD in patients with MS are discussed. Particular attention is paid to an integrated approach to the treatment of patients with CKD aimed at reducing the risk of CKD progression and cardiovascular events.
Villevalde et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: